- Home
- FLNG vs NEO Comparison
FLNG vs NEO Comparison
Compare FLNG & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNG
- NEO
- Stock Information
- Founded
- FLNG 2006
- NEO 2001
- Country
- FLNG Bermuda
- NEO United States
- Employees
- FLNG N/A
- NEO N/A
- Industry
- FLNG Marine Transportation
- NEO Precision Instruments
- Sector
- FLNG Consumer Discretionary
- NEO Health Care
- Exchange
- FLNG Nasdaq
- NEO Nasdaq
- Market Cap
- FLNG 1.3B
- NEO 965.2M
- IPO Year
- FLNG N/A
- NEO 1999
- Fundamental
- Price
- FLNG $23.91
- NEO $7.28
- Analyst Decision
- FLNG Hold
- NEO Buy
- Analyst Count
- FLNG 1
- NEO 9
- Target Price
- FLNG $23.00
- NEO $13.31
- AVG Volume (30 Days)
- FLNG 315.9K
- NEO 1.7M
- Earning Date
- FLNG 05-21-2025
- NEO 04-29-2025
- Dividend Yield
- FLNG 12.55%
- NEO N/A
- EPS Growth
- FLNG N/A
- NEO N/A
- EPS
- FLNG 1.91
- NEO N/A
- Revenue
- FLNG $354,551,000.00
- NEO $672,361,000.00
- Revenue This Year
- FLNG N/A
- NEO $13.95
- Revenue Next Year
- FLNG $3.64
- NEO $11.16
- P/E Ratio
- FLNG $12.51
- NEO N/A
- Revenue Growth
- FLNG N/A
- NEO 10.10
- 52 Week Low
- FLNG $19.46
- NEO $6.08
- 52 Week High
- FLNG $29.18
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- FLNG 53.17
- NEO 38.30
- Support Level
- FLNG $22.24
- NEO $7.28
- Resistance Level
- FLNG $24.25
- NEO $7.63
- Average True Range (ATR)
- FLNG 0.60
- NEO 0.37
- MACD
- FLNG -0.08
- NEO -0.00
- Stochastic Oscillator
- FLNG 56.00
- NEO 12.42
About FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.